CA-4948
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndromes
Conditions
Myelodysplastic Syndromes, Anemia
Trial Timeline
Jan 1, 2022 → Jul 31, 2024
NCT ID
NCT05178342About CA-4948
CA-4948 is a phase 2 stage product being developed by Curis for Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT05178342. Target conditions include Myelodysplastic Syndromes, Anemia.
What happened to similar drugs?
7 of 19 similar drugs in Myelodysplastic Syndromes were approved
Approved (7) Terminated (7) Active (7)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05178342 | Phase 2 | Terminated |
Competing Products
20 competing products in Myelodysplastic Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 23 |
| JSP191 | Jasper Therapeutics | Phase 1 | 11 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 15 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 14 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 35 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 35 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 35 |
| decitabine + decitabine | Eisai | Phase 2 | 35 |
| decitabine + azacitidine | Eisai | Approved | 35 |
| Decitabine | Eisai | Phase 2 | 27 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 29 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 35 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 21 |
| Decitabine | Eisai | Phase 2 | 35 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 38 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 32 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 24 |
| Decitabine | Johnson & Johnson | Phase 2 | 35 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 27 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 35 |